These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9934808)

  • 21. [Intracavernous pharmacotherapy for treatment and evaluation of impotence].
    Vardi Y; Lidgi S; Moskovitz B; Levin RD
    Harefuah; 1991 Oct; 121(7-8):223-5. PubMed ID: 1783307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intracavernous injections: still the gold standard for treatment of erectile dysfunction in elderly men.
    Richter S; Vardi Y; Ringel A; Shalev M; Nissenkorn I
    Int J Impot Res; 2001 Jun; 13(3):172-5. PubMed ID: 11525316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calcitonin-gene-related peptide: a possible role in human penile erection and its therapeutic application in impotent patients.
    Stief CG; Wetterauer U; Schaebsdau FH; Jonas U
    J Urol; 1991 Oct; 146(4):1010-4. PubMed ID: 1895414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical evaluation of intracavernous self-injection of vasoactive drugs for impotence: a long-term follow-up observation].
    Hayashi S; Iwai Y; Yasumoto R; Matsuda J; Kawano M; Omachi T; Kono T; Yamamoto S; Sakakura T; Minami H
    Hinyokika Kiyo; 1994 Jan; 40(1):37-41. PubMed ID: 7509119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determinants of satisfactory rigidity after intracavernosal injection with prostaglandin E1 in men with erectile failure.
    Purvis K; Brekke I; Christiansen E
    Int J Impot Res; 1996 Mar; 8(1):9-16. PubMed ID: 8735188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Response to intracavernous administration of 3 different drugs in the same group of patients with erectile dysfunction].
    Ribé N; Rajmil O; Bassas L; Jurado C; Pomerol JM
    Arch Esp Urol; 2001 May; 54(4):355-9. PubMed ID: 11455770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three-year outcome of a progressive treatment program for erectile dysfunction with intracavernous injections of vasoactive drugs.
    Baniel J; Israilov S; Engelstein D; Shmueli J; Segenreich E; Livne PM
    Urology; 2000 Oct; 56(4):647-52. PubMed ID: 11018623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comprehensive history of injection therapy for erectile dysfunction, 1982-2023.
    Porst H; Lewis R; Virag R; Goldstein I
    Sex Med Rev; 2024 Jun; 12(3):419-433. PubMed ID: 38644056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The change of penile blood thromboxane B2 and prostacyclin after intracavernous injection of vasoactive drugs for the treatment of arteriogenic impotence.
    Lin JS; Chang WC; Lui SM
    Proc Natl Sci Counc Repub China B; 1994 Jan; 18(1):12-6. PubMed ID: 8029369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A dose-response study of alprostadil sterile powder (S.Po.) (Caverject) for the treatment of erectile dysfunction in Korean and Indonesian men.
    Choi HK; Adimoelja A; Kim SC; Soebadi DM; Seong DH; Garceau RJ
    Int J Impot Res; 1997 Mar; 9(1):47-51. PubMed ID: 9138059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy.
    Engel JD; McVary KT
    Urology; 1998 May; 51(5):687-92. PubMed ID: 9610580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Papaverine plus prostaglandin E1 versus prostaglandin E1 alone for intracorporeal injection therapy.
    Zaher TF
    Int Urol Nephrol; 1998; 30(2):193-6. PubMed ID: 9607891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction.
    Kaplan SA; Reis RB; Kohn IJ; Shabsigh R; Te AE
    Urology; 1998 Nov; 52(5):739-43. PubMed ID: 9801091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prostaglandin E1 injection in erectile dysfunction. Current diagnostic and therapeutic possibilities].
    Schrey A
    Fortschr Med; 1990 Oct; 108(30):577-80. PubMed ID: 2245960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Intracavernous injections in the treatment of erectile dysfunction in spinal cord injured patients: experience with 36 patients].
    Lebib Ben Achour S; Laffont I; Boyer F; Boiteau F; Dizien O
    Ann Readapt Med Phys; 2001 Feb; 44(1):35-40. PubMed ID: 11587653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Objective double-blind evaluation of erectile function with intracorporeal papaverine in combination with phentolamine and/or prostaglandin E1.
    Allen RP; Engel RM; Smolev JK; Brendler CB
    J Urol; 1992 Oct; 148(4):1181-3. PubMed ID: 1404632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erectile dysfunction in spinal cord injury: a cost-utility analysis.
    Mittmann N; Craven BC; Gordon M; MacMillan DH; Hassouna M; Raynard W; Kaiser A; Lanctôt LK; Tarride JE
    J Rehabil Med; 2005 Nov; 37(6):358-64. PubMed ID: 16287667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors for an early increase in dose of vasoactive agents for intracavernous pharmacotherapy.
    Kim SC; Seo KK; Park BD; Lee SW
    Urol Int; 2000; 65(4):204-7. PubMed ID: 11112870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drop-out reasons and complications in self-injection therapy with a triple vasoactive drug mixture in sexual erectile dysfunction.
    Casabé A; Bechara A; Cheliz G; Romano S; Rey H; Fredotovich N
    Int J Impot Res; 1998 Mar; 10(1):5-9. PubMed ID: 9542684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of effects following the intracorporeal injection of papaverine and prostaglandin E1.
    Chen JK; Hwang TI; Yang CR
    Br J Urol; 1992 Apr; 69(4):404-7. PubMed ID: 1581812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.